Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus by Aldo Ferreira-Hermosillo et al.
METABOLIC SYNDROME
DIABETOLOGY & 
Ferreira-Hermosillo et al. Diabetology & Metabolic Syndrome 2014, 6:32
http://www.dmsjournal.com/content/6/1/32RESEARCH Open AccessUtility of the waist-to-height ratio, waist
circumference and body mass index in the
screening of metabolic syndrome in adult
patients with type 1 diabetes mellitus
Aldo Ferreira-Hermosillo1, Claudia Ramírez-Rentería1, Victoria Mendoza-Zubieta2 and Mario A Molina-Ayala2*Abstract
Background: The incidence of macrovascular complications and morbidities associated to metabolic syndrome are
increasing in patients with type 1 diabetes mellitus (T1DM). The combination of T1DM with features of insulin
resistance similar to that of type 2 diabetes (T2DM), sometimes called “double diabetes”, has been associated with
central obesity. Since the most methods to accurately detect body fat and insulin resistance are not readily
available, we propose that certain indirect indexes for detecting obesity as waist-to-height ratio, waist circumference
and body mass index, may be useful when screening for metabolic syndrome in patients with T1DM.
Methods: We performed a transversal evaluation (clinical and biochemical) in all the patients of the T1DM Clinic
(n = 120). We determined the presence of metabolic syndrome according to the Joint Statement Criteria by the
American Heart Association/ National Heart Lung and Blood Institute and the International Diabetes Federation and
the utility of certain anthropometric indexes for predicting double diabetes was evaluated.
Results: Thirty seven percent of the patients were considered to have metabolic syndrome using these criteria
(n = 30). These patients were significantly older (p = 0.002), have a higher glycated hemoglobin (p = 0.036), cholesterol
(p < 0.012) and triglyceride concentration (p < 0.01) as well as body mass index (p = 0.004), waist circumference (p = 0.01)
and waist-to-height ratio (p < 0.01) than the group without metabolic syndrome. Also their c-HDL is lower (p < 0.01). A
value of 0.52 for waist-to-height ratio correctly classified the largest number of patients (68% of correctly classified) well
as the waist circumference (66% of correctly classified) with an adequate specificity and sensibility. Meanwhile the most
precise body mass index value only classified correctly to 61% of patients.
Conclusion: Our data show that waist circumference and waist-to-height ratio indexes are useful to predict the presence
of metabolic syndrome in adult patients with type 1 diabetes mellitus.
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Type 1 diabetes mellitus (T1D) is an autoimmune dis-
ease in which pancreatic β cells are destroyed, generat-
ing an incapacity to maintain appropriate insulin and
glucose concentrations [1]. The Instituto Mexicano del
Seguro Social (IMSS) is a governmental institution that* Correspondence: mmol_17@yahoo.com.mx
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article, unless otherwise stated.provides medical health for approximately 30% of the
Mexican population. One of its recent publications re-
ported a significant increase in the incidence of type 1
diabetes in the population evaluated by this healthcare
system. Between the years 2000 and 2010, for the group
under 19 years of age, the incidence increased from 3.4
to 6.2 per 100,00 in both sexes (p <0.001) [2].
Diabetes is one of the main causes of incapacity world-
wide and affects all age groups. Years ago, microvascular
complications, such as nephropathy, constituted the
main cause of morbidity and mortality among patientsed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in the macrovascular complication rate, associated with
the presence of other cardiovascular risk factors such as
hypertension, hypertriglyceridemia, hypoalphalipoprotei-
nemia and central obesity, all of them in the context of
metabolic syndrome (MS) [4]. Mexico has one of the lar-
gest prevalence in obesity worldwide, which has also af-
fected the population with T1D [5]. Teupe and Bergis
described the presence of pathologies commonly associ-
ated with type 2 diabetes in patients with T1D and
named them “double diabetes” [6]. Even when there have
been controversies regarding the use of this term and
its diagnosis, these associations are being reported fre-
quently. The treatment costs and complications will the-
oretically increase in the next years in patients fulfilling
the criteria for MS. Accurate screening, early diagnosis
and prevention will be important interventions for this
group in the upcoming years.
The pathophysiology of MS is complex and it is yet
being investigated. It has been hypothesized that the in-
creased visceral adiposity in central obesity is a cardinal
factor. Fat is a highly metabolic tissue that generates adi-
pokines, greatly responsible for the development of insu-
lin resistance [7]. Specific methods for visceral adiposity
quantification such as axial tomography, magnetic res-
onance and electric bioimpedance are expensive and, for
the most part, inaccessible in developing countries [8].
Therefore, surrogate measurements such as body mass
index (BMI) and waist circumference (WC) have been
used to assess the risk of MS [9]. All of them have ser-
ious limitations: race and clinical characteristics are two
of the major determinants for the different results pub-
lished by each author, making it necessary to validate
every index for our specific population.
The waist-to-height ratio (WHtR) has proved to be a
better discriminator for the metabolic and cardiovascular
risk factors, however, studies differ in their cut-off values
and usefulness to detect MS in general population [10].
To our knowledge, this information is not yet available
for the population with T1D.
The purpose of this study was to evaluate and com-
pare the utility of WHtR, BMI and WC in the detection
of MS in patients with T1D and proposing specific cut-
off values for the Mexican population.
Methods
We performed a transversal evaluation in all the patients
in the Type 1 Diabetes Clinic (Hospital de Especialidades
Centro Médico Nacional Siglo XXI, tertiary referral
center). We included 120 patients with the following
characteristics: 18 years of age or older, at least 3 regular
yearly visits to the clinic, no infections recorded in the
3 months previous to the study and no change in insulin
dose during the same time. Patients with incompleterecords or follow-ups, poor treatment adherence and pri-
mary dyslipidemias were excluded. The study completed
all the requirements of the local ethics committee (Comite
Local de Investigación y Ética en Investigación en Salud).
The protocol and the aim of the study were fully explained
to the subjects, who gave their written consent.
Diagnostic criteria for MS
We used the joint statement criteria by the American
Heart Association/National Heart Lung and Blood
Institute (AHA/NHLBI) and the International Diabetes
Federation (IDF) [11]. Patients were considered to
have MS with 3 or more of the following components:
serum triglycerides >150 mg/dl (1.7 mmol/l), serum
high-density lipoproteins cholesterol (c-HDL) <40 mg/dl
(1.03 mmol/l) in men and <50 mg/dL (1.29 mmol/l) in
women or a previously treated dyslipidemia, arterial blood
pressure >130/85 mmHg in two different determination or
patients receiving treatment with antihypertensive drugs.
WC >90 cm in men and >80 in women. Since patients
were treated for type 1 diabetes, they all fulfilled the cri-
teria of fasting plasma glucose >100 mg/dl (5.6 mmol/l)
at least once.
Anthropometric measurements
At the time of evaluation we registered weight (kilograms)
and height (meters), as well as WC (centimeters). A single
investigator, using the same calibrated scale with an in-
tegrated stadiometer, performed anthropometric mea-
surements. WC was determined at the middle point
between the inferior rim of the last costal arch and the
superior rim of the anterosuperior iliac spine. BMI was
calculated as the weight divided by height to the square.
Blood pressure was determined in the left arm, after
10 minutes in a resting position, during a fasting state,
without coffee or tobacco ingestion in the last week. The
sphygmomanometer was calibrated and values were aver-
aged after 2 different measurements with a 5-minute dif-
ference between them.
Biochemical determinations
Laboratory results were obtained with a 6 mL sample
in BD Vacutainer (BD Franklin Lakes, New Jersey
USA), centrifuged at 3150 x g for 15 minutes and
serum was then analyzed with a kit for glucose, choles-
terol, c-HDL and triglycerides (COBAS 2010 Roche
Diagnostics, Indianapolis USA) using photocolorimetry
with spectrophotometer Roche Modular P800 (2010 Roche
Diagnostics, Indianapolis USA). c-HDL samples were
treated with enzymes modified with polyethileneglycol
and dextrane sulphate, analyzed with the same photo-
colorimetric technique. Glycated hemoglobin (HbA1c)
was evaluated by turbidimetric immunoanalysis (COBAS
2010 Roche Diagnostics, Indianapolis USA). c-LDL was
Table 1 Baseline characteristics of the population
comparing patients with metabolic syndrome (MS)
and without MS
Parameter
With MS Without MS
p
(n = 30) (n = 90)
Age (years) 35 (26–42) 28 (20–34) 0.002*





Smoking status 5% 18% 0.551
Insulin dose (U/day) 49 (40–69.8) 45.5 (39–57) 0.086*
(U/kg/day) 0.69 (0.52–0.98) 0.75 (0.59–0.97) 0.974
Weight (m) 1.62 (1.57–1.70) 1.66 (1.55–1.67) 0.269
BMI (kg/m2) 25 (23.8–28.7) 23.3 (21.3–26.4) 0.004*
WC (cm) 90.4 ± 10.7 79.6 ± 8.2 <0.01†
Male 92.1 ± 12.6 85.2 ± 6.1 0.032
Female 89.6 ± 10.3 77.2 ± 7.88 <0.01
WHtR 0.54 (0.51–0.60) 0.49 (0.46–0.53) <0.001*
Hypertension 14% 8% <0.01‡
Dyslipidemia 18% 16% 0.02‡
Glycated hemoglobin (%) 8.8 (8–10) 8.2 (7.5–9.3) 0.036*
Total colesterol (mg/dl) 188 (169–210) 174.5 (153–206) <0.012*
Tryglycerides (mg/dl) 175 (136–248) 88 (66–113) <0.01*
c-HDL (mg/dl) 46 (37–53) 57 (48–66) <0.01*
Male 41 (37–48) 49 (44–60) 0.044
Female 47 (37–55) 60 (53–69) <0.01
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CT mg/dl – (c-HDL mg/dl + triglycerides mg/dl/5) if
triglycerides were <400 mg/dl [12].
Statistic analysis
Data were analyzed with STATA v.11. Kolmogorov-
Smirnov test was used to determine normality. Results
are expressed accordingly with means and standard devi-
ations (SD) or medians and interquartile ranges (IQR).
To establish associations between quantitative variables,
Student t test or Mann–Whitney U test were used.
Qualitative variables were associated with χ2 or Fisher
tests. Receiver Operating Characteristic curves (ROC)
for the different indexes and their combinations were
used to identify the best cut of point with 95% confi-
dence intervals. The areas under the curve (AUC) were
compared with χ2. Additionally correlations where per-




Thirty seven percent of the patients were considered to
have MS using these criteria (n = 30). Table 1 compares
the baseline characteristics of the populations with and
without MS. Patients with MS are significantly older,
have higher BMI, WC and WHtR than the group with-
out MS. Also, their HbA1c, cholesterol and triglycer-
ide concentrations are higher while c-HDL is lower.
This group had higher prevalence of hypertension and
dyslipidemia.
We performed a ROC curve for WHtR, BMI and WC
in our population to determine the best cut off points to
predict MS in our population (Figure 1).
Table 2 depicts the best cut off values, sensibility,
specificity, likelihood ratio positive (LR+) and negative
(LR-) predictive values and the percentage of correctly
classified patients with each index. Likelihood ratios
were used for assessing the value of performing these
tests. A LR + higher than 1 indicates the test could be
used to confirm the disease while a lower LR- indicates
the test could be used to rule out the disease. The cut-
off points were selected using Youden index, at which
(sensitivity + specificity −1) is maximized [13]. A value
of 0.52 for WHtR correctly classifies the largest number of
patients with an adequate specificity and sensibility. This
cut off was also appropriate for both sexes. When stratified,
the male sub group had an AUC of 0.67 (0.48 – 0.85), sens-
ibility of 62%, specificity of 61% and also 61% of correctly
classified patients. In female patients the AUC was 0.79
(0.69 – 0.88), sensibility was 74%, specificity 68% and 70%
of patients classified correctly (complementary data not
shown). According to our results the WC cutoff value of
85 cm has lower sensitivity, specificity and detects fewerpatients with MS compared to WHtR. Nevertheless, using
cutoff values of 90 cm for men and 80 cm for women as
recommended by IDF, increases the number of patients
correctly classified to 76 and 73%, respectively.
Considering that the patients with MS are older than
patients without MS, we performed a Pearson correl-
ation test. This test showed a small but positive correl-
ation between age and WC (ρ=0.217; p = 0.017) but
there was no correlation with WHtR index (p = 0.063).
Nevertheless, there was a positive correlation in patients
under 30 years of age (ρ=0.261, p = 0.039) which is not
observed in older patients (p = 0.773). We didn’t observe
any direct association between gender and MS even after
dividing by age groups. Nevertheless if WC cutoff points
are adjusted to gender, it reaches a MS detection of 76%
for male and 73% for female.
Regarding the predictive power of BMI to detect MS, we
found that the traditional cutoff value used to predict ex-
cess weight (BMI >25 kg/m2) had a sensibility of only 57%
Figure 1 ROC curves for WC, WHtR and BMI. The ROC curves were performed to evaluate the best cut-off value for predicting metabolic
syndrome in our population. WC =waist circumference, WHtR = waist-to-height ratio and BMI = body mass index.
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off for obesity (BMI >30 kg/m2) had a lower sensibility
(13%) but a high specificity (98%) with a precision of 67%.
These indexes may be proposed as one more of the
screening tools easily available for clinicians in all cen-
ters. However, no single index seems to provide by itself
the combination of high sensibility and specificity re-
quired for most diagnostic tests. However, the combin-
ation of these indexes may be helpful. For instance,
combining the WHtR cutoff point of 0.52 with the BMI
cutoff point of 24 kg/m2 presented a sensibility of 59%,
but increased specificity to 83%, LR(+) 3.45, LR(−) 0.5
and a precision of 77%. When we analyzed the com-
monly used WHtR cutoff point of 0.5 and the cutoff of
value for BMI of 25 kg/m2 we observed a lower sensibil-
ity of 52% with a similar high specificity of 81%, LR(+)
2.72, LR(−) 0.59 and a precision of 74%.
On the contrary, combining the WHtR cutoff point of
0.5 with the BMI cutoff point for obesity (30 kg/m2), in-
creases sensibility to 86% with a lower, but useful specifi-
city of 66%, LR(+) 2.55, LR(−) 0.22, however precision is
only 14%.Table 2 Best cutoff values to predict metabolic syndrome
Index AUC (IC 95%) Cut off value Sensibility S
WHtR 0.75 (0.66–0.84) 0.52 70%
WC 0.76 (0.67–0.85) 85 cm 66%
Men 0.71 (0.49–0.93) 90 cm 69%
Women 0.80 (0.70–0.90) 80 cm 90%
BMI 0.66 (0.56–0.76) 24 kg/m2 78%
LR+: positive likelihood ratio. LR-: negative likelihood ratio. WHtR: waist-to-height raFinally, using the χ2 test to evaluate the differences be-
tween the AUC, we found that when we used BMI as a
reference parameter, both WHtR and WC predicted MS
better (AUC BMI 0.65 vs AUC WHtR 0.74, p = 0.028
and AUC WC 0.76, p = 0.017). We didn’t find any statis-
tically significant difference between WHtR and WC
(p = 0.44).Discussion
Our study included a total of 120 adult patients with
T1D (>18 years old) where we found a shocking 37% of
patients fulfilling current criteria for MS using current
diagnostic tools. Eighteen percent had dyslipidemia and
14% were hypertensive.
Recent data show that diagnosing and treating MS
should be new concern for clinicians treating T1DM
populations, considering the possibility of higher cardio-
vascular risk associated with it; however, the stratifica-
tion is currently based on laboratory data, after the
biochemical alterations are present [14]. To date, there
is no single clinical, inexpensive, easily available index to
predict the presence of MS in T1DM patients. Clinicalpecificity % of correctly classified patients LR+ LR-
66% 68% 2.05 0.44
65% 66% 1.89 0.52
81% 76% 3.63 0.38
63% 73% 2.42 0.15
58% 61% 1.81 0.39
tio. WC: waist circumference. BMI: body mass index.
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that may be candidates for additional interventions and
studies. Primary prevention and low costs are important
concerns for these decisions, especially in developing
countries. Simple, but validated anthropometric mea-
surements may be useful tools for these ends [15].
Our results are different from our previously reported
data where the prevalence was 25% using the National
Cholesterol Education Program: Adult Treatment Panel
III (NCEP:ATPIII) criteria [16] and with the results of
Thorn, et al. in the Finnish population (38% men, 40%
women) [17]. We should consider the difficulties and
controversies defining MS in T1DM patients and the
limitations of using only clinical and general laboratory
data in our study. Since all the patients had elevated
serum glucose at least once, and this parameter is in-
cluded as a diagnostic criterion, it could overestimate
the prevalence of MS but if it is not considered, MS
could be underestimated. However the same limitation
will affect other publications if no other accurate system
is proposed for the specific T1DM population.
Determining insulin resistance may also prove difficult
in these patients. The gold standard to assess insulin re-
sistance is the hyperinsulinemic euglycemic clamp. [18]
However, this procedure is complex, expensive and it is
usually not performed as part of the everyday evaluation
of patients. It has been proposed that insulin dose could
discriminate patients with insulin resistance; however, this
is unreliable because it is inaccurately reported by patients
and the potential effect of residual endogenous insulin se-
cretion [19]. Nowadays, eGDR (estimated glucose disposal
rate) index has been proposed for determining insulin
resistance in patients with T1D. This study appears to ad-
equately correlate with the clamp technique. [20] At this
time, studies are being carried out to calculate specific cut-
off points for this index in the Mexican population.
Clearly, MS in T1DM was a fairly unknown phe-
nomenon until recent years. Along with the increasing in-
cidence in obesity, T1DM patients are developing more
features previously associated only with T2DM and may
have higher cardiovascular risk in the future. A study in
the Pittsburgh Epidemiology of Diabetes Complications
(EDC) cohort studied 589 patients and showed a change in
the BMI of T1DM patients in the last 20 years [21]. They
found that obesity (BMI >30 kg/m2) rose up to 22.7% and
overweight population (BMI 25–30 kg/m2) increased from
26 to a staggering 42% [22]. In the Mexican population,
this increased weight has been attributed to two different
but related factors: an exposure to calorie-rich diets and
the over-insulinization associated with the intensive con-
trol therapies for T1D [23].
We don’t know yet the exact mechanisms by which
MS increases the risk of cardiovascular events. Obesity
may be a central factor in the pathophysiology of “doublediabetes”. Some theories propose the participation of
inflammatory cytokines secreted by the adipose tissue,
known to generate atherothrombosis in type 2 diabetes
[24-26]. Other studies have associated the increasing insu-
lin concentrations to the stimulation of 11 β- hydroxyste-
roid dehydrogenase, which modifies the differentiation
from fibroblasts to adipocytes and transformation from
cortisone to the highly active cortisol [27].
Clinical data is important to detect risk factors for car-
diovascular disease. BMI is one of the most frequently
used indexes to detect obesity, however it can’t discrim-
inate between excess adiposity and muscle mass [28]
and it does not detect abdominal obesity. In our study
we found that the traditionally used cut-off values to de-
tect obesity had low sensibilities for MS. Another index,
the WC correlates better with the abdominal adipose tis-
sue and has been successfully associated with cardiovas-
cular risk by different authors [29]. This index, however,
may underestimate the real cardiovascular risk in patients
with small stature, which may be important in many
groups, such as ours [30].
It is still controversial which of the tree indexes is bet-
ter predicting the development of MS. A Chinese study
found that these three markers were useful to detect MS
[31]. In the San Antonio Heart Study, BMI and WC were
found to be equally useful in the Mexican-american popu-
lation [32]. The INTERHEART study [33] and Bener, et al.
[34] found that WC was the best index, while Ashweel,
et al. found in 31 studies that WHtR was the best predictor
[35]. It would seem that different ethnic groups require dif-
ferent indexes and that cut-off values must be standardized
for each one of them.
Regarding the Mexican population, Elizondo-Montemayor,
et al. found that children aged 6–12 years with the
diagnosis of overweight and obesity had a 23% of MS
with a cut off value of 0.59 LR(+) 3.80, LR(−) 0.232,
sensibility of 81.8% and specificity of 78.5%, in contrast
with the value of 0.50 found in the literature, which is
supposed to have a sensibility of 100%, with a specificity
of only 22.7%, LR(+) 1.29 and LR(−) 0.000 [36]. The same
study showed that the 90th percentile of WC had a preci-
sion of 82.6%, while the 97th percentile of BMI had a pre-
cision of 76%.
However, none of these results reflects the adult popu-
lation with T1D, which tends to be more obese. Our re-
sults show that there is a correlation between some of
these indexes and age, but only in patients under 30 years
of age. This may be due to the fact that all older patients
tend to gain weight whether they develop MS or not.
This may also mean that it could be more difficult to de-
tect MS in T1DM patients as age increases and it confirms
the need for preventive interventions at young ages.
In the current study, we found WC and WHtR to be
the best predictive indexes for MS with a cut-off value
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WC were highly sensitive and specific.
The preference of sensitivity vs specificity depends on
the objective of the diagnostic tool. Most screening tools
are selected when they are highly sensitive because of
the reduced chance of false negative results and they are
very useful when screening open populations, however
higher specificities are required when we want to deter-
mine which patients should be referred for further
evaluation given the high probabilities of MS. The final
choice of one over the other may be in the hands of the
clinician when a specific case presents before him.
On the other hand, for patients with a BMI over
24 kg/m2, the precision is high and using this index as a
gold standard WC and WHtR are better markers for
MS. This BMI cutoff is lower than the one proposed
internationally to diagnose the overweight population,
which suggests that our group may require a different
set of diagnostic indexes in order to predict their cardio-
vascular risk.
This study is the first one to describe the utility of
these indexes in adult patients with T1D. Using a clinical
index is not a substitute for laboratory and specialized
workup, however, when properly validated, may be a
useful tool for clinicians worldwide. We propose that the
combination of these simple indexes may be helpful for
this and other larger populations similar to ours. Pro-
spective studies with larger cohorts may be necessary to
determine if it is applicable in other ethnic groups, their
specific cut off points and the differentiation between
sexes and age groups.
Conclusion
WC and WHtR indexes are useful to predict the pres-
ence of metabolic syndrome in adult patients with T1D.
We found that the WHtR index and WC allow for discrim-
ination of patients with T1D and an increased probability
of metabolic syndrome. The cut-off value of WHtR of 0.52
was the most accurate (68%) to discriminate MS in
Mexican T1D. In ethnic groups where height variations
could interfere with the precision of other indexes, WHtR
could be a simple and useful tool to screen for cardiovas-
cular risk factors in type 1 diabetes population.
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